Analyst Reco. MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/01/2026 GMT			Pre-market 23:38:45
5.770 ^USD	-1.37%		5.725	-0.78%

01-08	MannKind provides business updates and 2026 growth drivers	RE
12-23	MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention	MT

Analyst Reco.

11-11	RBC Lowers Price Target on MannKind to $7.50 From $8, Keeps Outperform Rating	MT
11-11	Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating	MT
13/10/25	MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says	MT
13/10/25	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE
05/09/25	Oppenheimer Adjusts MannKind Price Target to $15 From $12, Maintains Outperform Rating	MT
26/08/25	RBC Raises Price Target on MannKind to $8 From $7, Keeps Outperform Rating	MT
07/08/25	RBC Cuts Price Target on MannKind to $7 From $8, Keeps Outperform Rating	MT
06/08/25	Biotech firm MannKind's Q2 revenue rises 6%	RE
23/07/25	RBC Cuts Price Target on MannKind to $8 From $10, Keeps Outperform Rating	MT
10/04/25	Mizuho Initiates MannKind at Outperform With $12 Price Target	MT
10/02/25	Wedbush Initiates MannKind at Outperform With $11 Price Target	MT
20/12/24	MannKind Shares Rise After Wells Fargo Begins Coverage	MT
20/12/24	Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target	MT
19/12/24	RBC Upgrades MannKind to Outperform From Sector Perform, Raises Price Target to $10 From $7	MT
14/11/24	Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7	MT
08/11/24	RBC Capital Adjusts Price Target on MannKind to $7 From $5, Maintains Sector Perform Rating	MT
28/08/24	Oppenheimer Adjusts MannKind Price Target to $12 From $10, Maintains Outperform Rating	MT
14/11/23	Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	MT
10/10/23	Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	MT
14/08/23	HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	MT
27/02/23	HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating	MT
09/11/22	SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating	MT
28/02/22	HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating	MT
14/05/21	MANNKIND : Initiated at Sector Perform by RBC, Price Target Set at $5/Share	MT
05/03/21	MANNKIND : SVB Leerink Adjusts Price Target on MannKind to $5 From $3, Maintains Outperform Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Analyst Reco.

Filters